Recently, the Class 1 innovative drug Netanasvir Phosphate Capsules (trade name: 东卫卓/Dongweizhuo) of Sunshine Lake Pharma Co., Ltd. is approved for marketing by China NMPA. This product is indicated for use in combination with Encofosbuvir Tablets for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, or 6, who are either treatment-naïve or have been previously treated with interferon, with or without compensated liver cirrhosis. The marketing of this drug provides a new treatment option for relevant patients.